Eric Eisenhauer
YOU?
Author Swipe
View article: 102P Interim safety analysis of a phase II trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
102P Interim safety analysis of a phase II trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer Open
Vulvar cancer is a rare disease with increasing incidence. Treatment can involve surgery and chemoradiation for local and regional disease, while systemic chemotherapy and immunotherapy are reserved for patients with distant metastases. Pa…
View article: Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
PDF file - 440K, Supplementary Figure 1. DDB2 expression is inversely correlated with Bcl-2 expression in human ovarian cancer cells and tissues. Supplementary Figure 2. Recruitment of transcription factor E2F1 and Sp1 to the bcl-2 promote…
View article: Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1…
View article: Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. DNA damage-binding protein complex subunit 2 (DDB2) …
View article: Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
PDF file - 440K, Supplementary Figure 1. DDB2 expression is inversely correlated with Bcl-2 expression in human ovarian cancer cells and tissues. Supplementary Figure 2. Recruitment of transcription factor E2F1 and Sp1 to the bcl-2 promote…
View article: Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
FIGURE S1
View article: Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
Supplementary Figure 2
View article: Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
Supplementary Figure 2
View article: Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1…
View article: Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) Open
FIGURE S1
View article: Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
Data from DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells Open
Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. DNA damage-binding protein complex subunit 2 (DDB2) …
View article: NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022 Open
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for t…
View article: Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Open
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patie…
View article: Understanding and Targeting Apoptotic Pathways in Ovarian Cancer
Understanding and Targeting Apoptotic Pathways in Ovarian Cancer Open
Ovarian cancer cells evade the immune system as well as chemotherapeutic and/or biologic treatments through inherent or acquired mechanisms of survival and drug resistance. Depending on the cell type and the stimuli, this threshold can ran…